Insulet (PODD) Misses Q4 EPS by 22c, Guidance Comes in Light
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts PODD Hot Sheet
Price: $162.47 +4.91%
Financial Fact:
Other expense, net: -5.37M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Other expense, net: -5.37M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Insulet (NASDAQ: PODD) reported Q4 EPS of ($0.48), $0.22 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $100.1 million versus the consensus estimate of $91.89 million.
GUIDANCE:
Insulet sees Q1 2016 revenue of $77-80 million, versus the consensus of $83.19 million.
Insulet sees FY2016 revenue of $330-350 million, versus the consensus of $360.08 million.
For earnings history and earnings-related data on Insulet (PODD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Insulet (PODD) Tops Q3 EPS by 40c
- Datadog stock tumbles 19% despite earnings beat
- SharkNinja (SN) Tops Q3 EPS by 74c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
